Fingerprint
Dive into the research topics of 'A phase 2 study of momelotinib, a potent JAK1 and JAK2 inhibitor, in patients with polycythemia vera or essential thrombocythemia'. Together they form a unique fingerprint.- Sort by
- Weight
- Alphabetically
A phase 2 study of momelotinib, a potent JAK1 and JAK2 inhibitor, in patients with polycythemia vera or essential thrombocythemia
Srdan Verstovsek, Stephane Courby, Martin Griesshammer, Ruben A. Mesa, Carrie Baker Brachmann, Jun Kawashima, Julia D. Maltzman, Lixin Shao, Yan Xin, Daniel Huang, Ashish Bajel
Research output: Contribution to journal › Article › peer-review
19
Scopus
citations